INTELLIA THERAPEUTICS

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 11 2024 13:01:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

31 10 2024 06:45:01 提供 NetDania Notify

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

31 10 2024 04:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

30 10 2024 06:45:22 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

29 10 2024 08:48:28 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

24 10 2024 06:46:04 提供 NetDania Notify

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

24 10 2024 05:01:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 10 2024 06:45:05 提供 NetDania Notify

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

10 10 2024 04:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

07 10 2024 04:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

04 10 2024 07:23:57 提供 NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 10 2024 13:01:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

03 10 2024 06:45:08 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

02 10 2024 06:45:32 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

01 10 2024 10:25:49 提供 NetDania Notify

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

01 10 2024 04:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

12 9 2024 04:30:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

11 9 2024 07:45:32 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

10 9 2024 07:37:45 提供 NetDania Notify

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 9 2024 13:30:00 提供 Nasdaq GlobeNewswire